Back to today’s briefing

Story perspectives

SpringWorks Wins FDA Approval; Merck Eyes $4.1B Acquisition

2/12/2025

32 5

Summary

Story summary

SpringWorks Therapeutics has made a groundbreaking leap with FDA approval for Gomekli (mirdametinib), the first-ever treatment for neurofibromatosis type 1 (NF1) in patients aged 2 and up with inoperable plexiform neurofibromas. Meanwhile, Merck KGaA is eyeing a potential acquisition of SpringWorks, which has surged to a market cap of $4.1 billion.

1 of 1

Story summary

SpringWorks Therapeutics has made a groundbreaking leap with FDA approval for Gomekli (mirdametinib), the first-ever treatment for neurofibromatosis type 1 (NF1) in patients aged 2 and up with inoperable plexiform neurofibromas. Meanwhile, Merck KGaA is eyeing a potential acquisition of SpringWorks, which has surged to a market cap of $4.1 billion.